Nuvalent
Bookmark
ShareNuvalent is a company. It is in Cambridge, the United States and its CEO is James R. Porter. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Cambridge
- state: MA
- country: United States
- employees: 48 people
- revenues: Try Pro to see estimate
- sector: Health Care
- industry: Biotechnology
- CEO: James R. Porter
- ESG score: Try Pro to see estimate
- environmental score (ESG): Try Pro to see estimate
- social score (ESG): Try Pro to see estimate
- governance score (ESG): Try Pro to see estimate
See more facts
Extract data
Download datasets about Nuvalent:
Dataset of stocks from Nuvalent:
Nuvalent is one of the companies in Biotechnology, companies in Health Care, companies in Cambridge, companies in the United States and 3,456,835 companies in our database.
Talking Points
- Nuvalent | Precisely targeted therapies for patients with cancer
- With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
- Creating #preciselytargetedtherapies for patients with cancer, designed to overcome limitations of existing therapies for clinically proven kinase targets
- 11-50 employees Headquarters Cambridge, Massachusetts Type Privately Held Founded 2017 Locations Primary One Broadway 14th Floor Cambridge, Massachusetts 02142, US Get directions Employees at...
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
